所有图片(1)

文件

361275

3′-脱氧-3′-氟胸苷

Name: 3′-脱氧-3′-氟胸苷
Brand: ALDRICH

97%

别名:

3′-Fluoro-2′,3′-dideoxythymidine, 3′-Fluorodeoxythymidine

登录查看公司和协议定价

所有图片(1)

About This Item

经验公式（希尔记法）:

C₁₀H₁₃FN₂O₄

CAS号:

25526-93-6

分子量:

244.22

MDL號碼:

MFCD00056058

分類程式碼代碼:

41106305

PubChem物質ID:

24862180

NACRES:

NA.22

化驗

97%

形狀

solid

mp

176-178 °C (lit.)

儲存溫度

2-8°C

SMILES 字串

CC1=CN([C@H]2C[C@H](F)[C@@H](CO)O2)C(=O)NC1=O

InChI

1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1

InChI 密鑰

UXCAQJAQSWSNPQ-XLPZGREQSA-N

基因資訊

human ... TK2(7084)

正在寻找类似产品? 访问产品对比指南

應用

具有应用前景的抗病毒试剂，活性类似于其他 3′-脱氧-3′-取代胸苷。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.

Eliot T McKinley et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(3), 424-430 (2013-01-24)

Selective inhibition of oncogenic targets and associated signaling pathways forms the basis of personalized cancer medicine. The clinical success of (V600E)BRAF inhibition in melanoma, coupled with the emergence of acquired resistance, underscores the importance of rigorously validating quantitative biomarkers of

[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.

Nicolas Graf et al.

European journal of nuclear medicine and molecular imaging, 40(1), 34-43 (2012-10-12)

Positron emission tomography (PET) with the thymidine analogue [(18)F]fluorothymidine ([(18)F]FLT) has been shown to detect early response to chemotherapy in high-grade lymphoma. In this preclinical in vitro and in vivo study we compared [(18)F]FLT to the glucose analogue [(18)F]fluorodeoxyglucose ([(18)F]FDG)

Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.

Tyler J Bradshaw et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(11), 1931-1937 (2013-09-18)

Intratumor heterogeneity in biologic properties and in relationships between various phenotypes may present a challenge for biologically targeted therapies. Understanding the relationships between different phenotypes in individual tumor types could help inform treatment selection. The goal of this study was

3'-Fluoro-2',3'-dideoxy-5-chlorouridine: most selective anti-HIV-1 agent among a series of new 2'- and 3'-fluorinated 2',3'-dideoxynucleoside analogues.

A Van Aerschot et al.

Journal of medicinal chemistry, 32(8), 1743-1749 (1989-08-01)

A series of 2'- and 3'-fluorinated 2',3'-dideoxynucleosides and 3'-azido-2',3'-dideoxynucleosides were synthesized and evaluated for their inhibitory activity against human immunodeficiency virus-1 (HIV-1) replication in MT-4 cells. Neither conversion of 3'-fluoro- or 3'-azido-2',3'-dideoxyadenosine to the corresponding inosine derivatives nor 8-bromination of

Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.

Deniz Kahraman et al.

Clinical nuclear medicine, 37(11), 1058-1064 (2012-10-03)

The aim was to assess the value of tumor lesion glycolysis (TLG) and tumor lesion proliferation (TLP) determined by FDG and 3'-deoxy-3'-F-fluorothymidine (FLT) PET for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer (NSCLC) treated

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件